Characterisation of peripheral blood mononuclear cells in patients with combination ipilimumab and nivolumab therapy-related colitis

Documenti analoghi

• Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis
  di: Sasson, SC, et al.
  Pubblicazione: (2020)
• Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis
  di: Sasson, SC, et al.
  Pubblicazione: (2019)
• Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
  di: Serigne Lo, et al.
  Pubblicazione: (2020-10-01)
• Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation
  di: David Anson, et al.
  Pubblicazione: (2019-01-01)
• A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome
  di: Ian M. Bouligny, et al.
  Pubblicazione: (2025-02-01)